| 1 |
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration
David S. Liao et al. · Ophthalmology
Open access |
16 Jul 2019 |
527 |
| 2 |
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
Jeffrey S. Heier et al. · The Lancet
Open access263 authors |
Oct 2023 |
509 |
| 3 |
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen, Jeff Szer, Ilene Ceil Weitz et al. · New England Journal of Medicine
Open access |
17 Mar 2021 |
403 |
| 4 |
The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence–Based OCT Analysis
Sophie Riedl, Wolf‐Dieter Vogl, Julia Mai et al. · Ophthalmology Retina
Open access |
3 Jun 2022 |
104 |
| 5 |
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
Carlos de Castro, Federico V. Grossi, Ilene Ceil Weitz et al. · American Journal of Hematology
Open access |
28 Aug 2020 |
99 |
| 6 |
Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases
Bradley P. Dixon, Larry A. Greenbaum, Liwei Huang et al. · Kidney International Reports
Open access |
25 Aug 2023 |
94 |
| 7 |
Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy
Charles C. Wykoff, Philip J. Rosenfeld, Nadia Khalida Waheed et al. · Ophthalmology
Open access |
10 Mar 2021 |
91 |
| 8 |
Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood
Corinne J. Smith, Nikki L. Ross, Ali Kamal et al. · Frontiers in Immunology
Open access |
16 Sep 2022 |
83 |
| 9 |
Understanding Treatment Adherence in Chronic Diseases: Challenges, Consequences, and Strategies for Improvement
S. Patel, Ming‐Yi Huang, Sophia Miliara · Journal of Clinical Medicine
Open access |
26 Aug 2025 |
77 |
| 10 |
Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial
Régis Peffault de Latour, Jeff Szer, Ilene Ceil Weitz et al. · The Lancet Haematology
Open access |
30 Aug 2022 |
74 |
| 11 |
Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration
Muneeswar Gupta Nittala, Ravi Metlapally, Michael S. Ip et al. · JAMA Ophthalmology
Open access |
3 Feb 2022 |
66 |
| 12 |
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system
Sophie J. Bakri, Meryem Bektas, Darcie A. Sharp et al. · Journal of Managed Care & Specialty Pharmacy
Open access |
May 2023 |
65 |
| 13 |
Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
Raymond S. M. Wong, Juan Ramon Navarro-Cabrera, Narcisa Sonia Comia et al. · Blood Advances
Open access |
27 Feb 2023 |
62 |
| 14 |
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey
David Dingli, Joana E. Matos, Kerri Lehrhaupt et al. · Annals of Hematology
Open access |
2022 |
61 |
| 15 |
Inside-Out of Complement in Cancer
Martin V. Kolev, Madhumita Das, Monica R. Gerber et al. · Frontiers in Immunology
Open access |
Jul 2022 |
52 |
| 16 |
Efficacy and Safety of Pegcetacoplan in Kidney Transplant Recipients With Recurrent Complement 3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis
Andrew S. Bomback, Erica Daina, Giuseppe Remuzzi et al. · Kidney International Reports
Open access |
10 Oct 2024 |
51 |
| 17 |
Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan
Nathan C. Steinle, Ian Pearce, Jordi Monés et al. · American Journal of Ophthalmology
Open access |
3 Mar 2021 |
51 |
| 18 |
Disease Activity and Therapeutic Response to Pegcetacoplan for Geographic Atrophy Identified by Deep Learning-Based Analysis of OCT
Ursula Margarethe Schmidt-Erfurth, Julia Mai, Gregor Sebastian Reiter et al. · Ophthalmology
Open access |
14 Aug 2024 |
48 |
| 19 |
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
Fádi Fakhouri et al. · New England Journal of Medicine
Open access |
3 Dec 2025 |
47 |
| 20 |
Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes
Hansjürgen Agostini, Francis M. Abreu, Caroline R. Baumal et al. · Graefe s Archive for Clinical and Experimental Ophthalmology
Open access |
7 Jun 2024 |
47 |
| 21 |
With complements: C3 inhibition in the clinic
Martin V. Kolev, Tara Barbour, Scott B. Baver et al. · Immunological Reviews
Review |
25 Sep 2022 |
42 |
| 22 |
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer
Dorin Toader et al. · Molecular Cancer Therapeutics
Open access |
9 Jun 2023 |
41 |
| 23 |
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
Raymond S. M. Wong, Humphrey W. H. Pullon, Ismail Amine et al. · Annals of Hematology
Open access |
22 Jul 2022 |
41 |
| 24 |
Association of complement C3 inhibitor pegcetacoplan with reduced photoreceptor degeneration beyond areas of geographic atrophy
Maximilian Pfau, Steffen Schmitz-Valckenberg, Ramiro Ribeiro et al. · Scientific Reports
Open access |
25 Oct 2022 |
40 |
| 25 |
The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life
Jens Panse, Flore Sicre de Fontbrune, Pascale Burmester et al. · European Journal Of Haematology
Open access |
24 Jun 2022 |
39 |
| 26 |
The Pediocin PA-1 Accessory Protein Ensures Correct Disulfide Bond Formation in the Antimicrobial Peptide Pediocin PA-1
Camilla Oppegård, Gunnar Fimland, Jan Haug Anonsen et al. · Biochemistry
Open access |
30 Apr 2015 |
39 |
| 27 |
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs
Meryem Bektas, Catherine Copley‐Merriman, Shahnaz Khan et al. · Journal of Managed Care & Specialty Pharmacy
Open access |
Dec 2020 |
38 |
| 28 |
Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH
Morag Griffin, Richard J. Kelly, Jens Panse et al. · Blood Advances
Open access |
5 Feb 2024 |
34 |
| 29 |
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
Wendy Y. Cheng, Sujata P. Sarda, Nikita Mody‐Patel et al. · Advances in Therapy
Open access |
17 Jul 2021 |
32 |
| 30 |
APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers
Federico V. Grossi, Pauline Bedwell, Pascal Deschatelets et al. · Blood
|
2 Dec 2016 |
32 |
| 31 |
Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months
Dun Jack Fu, Pallavi Bagga, Gunjan Naik et al. · JAMA Ophthalmology
Open access |
9 May 2024 |
30 |
| 32 |
Prediction of visual function from automatically quantified optical coherence tomography biomarkers in patients with geographic atrophy using machine learning
Konstantinos Balaskas, Sophie L. Glinton, Tiarnán D L Keenan et al. · Scientific Reports
Open access |
16 Sep 2022 |
28 |
| 33 |
Humanistic and Economic Burden of Geographic Atrophy: A Systematic Literature Review
Sujata P. Sarda, Anne Heyes, Meryem Bektas et al. · Clinical ophthalmology
ReviewOpen access |
Dec 2021 |
27 |
| 34 |
Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease
Meryem Bektas, Catherine Copley‐Merriman, Shahnaz Khan et al. · Journal of Managed Care & Specialty Pharmacy
Open access |
Dec 2020 |
27 |
| 35 |
Deliberations of an International Panel of Experts on OCT Angiography Nomenclature of Neovascular Age-Related Macular Degeneration
Luísa S.M. Mendonça et al. · Ophthalmology
Open access |
25 Dec 2020 |
27 |
| 36 |
Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
Jennifer N. Rainho-Tomko, Vincent Pavot, Michael Kishko et al. · npj Vaccines
Open access |
30 Jun 2022 |
26 |
| 37 |
VALIANT: A Randomized, Multicenter, Double-Blind, Placebo (PBO)-Controlled, Phase 3 Trial of Pegcetacoplan for Patients with Native or Post-transplant Recurrent Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Carla Nester et al. · Journal of the American Society of Nephrology
|
Oct 2024 |
24 |
| 38 |
Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study
David F Cella, Sujata P. Sarda, Ray Hsieh et al. · Annals of Hematology
Open access |
23 Jul 2022 |
24 |
| 39 |
Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
Charles C. Wykoff, Frank Gerhard Holz, Allen Chiang et al. · American Journal of Ophthalmology
Open access |
23 Apr 2025 |
23 |
| 40 |
Developing Therapies for C3 Glomerulopathy
Carla Nester et al. · Clinical Journal of the American Society of Nephrology
Open access |
3 Jun 2024 |
23 |
| 41 |
Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia
Eloy Roman, Bruno Fattizzo, Merrill Kingman Shum et al. · Blood
Open access |
Nov 2024 |
21 |
| 42 |
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study
Christopher Jordan Patriquin, Andrija D. Bogdanovic, Morag Griffin et al. · Advances in Therapy
Open access |
4 Apr 2024 |
20 |
| 43 |
Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease
Severine A.R.A. Vermeire, Silvio Danese, William J. Sandborn et al. · Journal of Crohn s and Colitis
Open access |
14 Dec 2023 |
20 |
| 44 |
Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study
David S. Liao, Ravi Metlapally, Preeti G. Joshi · Immunotherapy
Open access |
21 Jul 2022 |
20 |
| 45 |
Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors
Peter Hillmen, Regina Horneff, Michael W. Yeh et al. · International Journal of Molecular Sciences
Open access |
31 Aug 2024 |
19 |
| 46 |
Progression of Geographic Atrophy
Ehsan Rahimy, Mujtaba Ali Khan, Allen C. Ho et al. · Ophthalmology Science
Open access |
19 Apr 2023 |
19 |
| 47 |
Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology
Meryem Bektas, Catherine Copley‐Merriman, Shahnaz Khan et al. · Journal of Managed Care & Specialty Pharmacy
Open access |
Dec 2020 |
19 |
| 48 |
DNA-specific selectivity in pairing of model nucleobases in the solid state
Tomislav Stolar, Stipe Lukin, Martin Etter et al. · Chemical Communications
Open access |
2020 |
19 |
| 49 |
Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial
Usha Chakravarthy, Roy Schwartz, Robyn H. Guymer et al. · American Journal of Ophthalmology
Open access |
13 Feb 2025 |
18 |
| 50 |
Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria
Régis Peffault de Latour, Morag Griffin, Richard Kelly et al. · Blood Advances
Open access |
9 Apr 2024 |
18 |